ADOCIA
Adocia operates as a biotechnology company specializing in tissue regeneration. Adocia was founded in 2005 as Proteins & Peptides Management S.A.S. and changed its name to Adocia in January 2008. Adocia is based in Lyons, France.
ADOCIA
Social Links:
Industry:
Alternative Medicine Biotechnology Therapeutics
Founded:
2005-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.adocia.com
Total Employee:
51+
Status:
Active
Contact:
+33472610610
Total Funding:
32 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Font Awesome Global Site Tag
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
CDC Enterprises
CDC Enterprises investment in Series B - Adocia
Idinvest Partners
Idinvest Partners investment in Series B - Adocia
Bioam Gestion
Bioam Gestion investment in Venture Round - Adocia
ACG Management
ACG Management investment in Venture Round - Adocia
Societe Generale Asset Management
Societe Generale Asset Management investment in Venture Round - Adocia
Idinvest Partners
Idinvest Partners investment in Venture Round - Adocia
Official Site Inspections
http://www.adocia.com Semrush global rank: 3.42 M Semrush visits lastest month: 3.99 K
- Host name: cluster028.hosting.ovh.net
- IP address: 51.91.236.193
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Adocia"
Adocia - Crunchbase Company Profile & Funding
Organization. Adocia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Adocia operates as a biotechnology company specializing in tissue regeneration. Adocia was …See details»
About - Adocia
With the development of the core technology BioChaperone ® (BC) aimed at optimizing the performance of therapeutic proteins while improving the ease-of-use by patients, Adocia has been recognized as a leader in the formulation of …See details»
ADOCIA - LinkedIn
ADOCIA | 10,669 followers on LinkedIn. "Innovative medicine for everyone, everywhere" | "Innovative medicine for everyone, everywhere" Listed on the Euronext stock market, Adocia is a clinical ...See details»
Adocia - Org Chart, Teams, Culture & Jobs - The Org
View Adocia's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. Log in. Sign up. Adocia. Track. Join to edit. …See details»
Adocia: Shareholders Board Members Managers and Company …
Nov 22, 2024 Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. …See details»
Adocia - Contacts, Employees, Board Members, Advisors & Alumni …
Organization. Adocia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of Board …See details»
Adocia Company Profile - Office Locations, Competitors, Revenue …
Adocia has 5 employees at their 1 location and €2.15 m in annual revenue in FY 2023. See insights on Adocia including office locations, competitors, revenue, financials, executives, …See details»
Investors - Adocia
Adocia is a biotechnology company specialized in the development of best-in-class medicines from already approved therapeutic proteins. Adocia is a French clinical-stage biotech company. The core activities of the company are to …See details»
History - Adocia
Soon after, Adocia announced two additional agreements with Tonghua Dongbao under which Tonghua Dongbao would supply Adocia with lispro and glargine insulins globally (excluding China). This partnership expands the panel of …See details»
Adocia - healthtechinnovationdays6.com
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has …See details»
Adocia Publishes its Letter to Shareholders - Yahoo Finance
LYON, France, November 23, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and …See details»
ADOCIA : Announces its Full Year Financial Results 2020 And …
Mar 18, 2021 Adocia Gérard Soula CEO [email protected] Ph: +33 4 72 610 610 www.adocia.com MC Services AG Adocia Press Relations Europe Raimund Gabriel …See details»
ADOCIA Reinforces Its Board of Directors with the Appointment of …
Jun 1, 2021 Adocia Adocia Gérard Soula CEO [email protected] Ph: +33 4 72 610 610 www.adocia.com MC Services AG Adocia Press Relations Europe Raimund Gabriel …See details»
ADOCIA Announces Its Annual Results for 2022 and Provides
Adocia, a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, …See details»
Medias and publications - Adocia
Jul 24, 2024 07/05/2023 ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million …See details»
ADOCIA Announces First Cell Therapy Preclinical Proof of Concept …
Sep 7, 2022 Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of iSee details»
Adocia - Adocia
Adocia was founded in 2005 by Gérard Soula and his two sons Olivier and Rémi. These three high-level scientists each had a PhD in polymer science and extensive experience in protein …See details»
ADOCIA Announces Its Annual Results for 2021 and ... - Business …
Apr 19, 2022 LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused …See details»
Delving into the Latest Updates on Adocia SA with Synapse
为合理配置研发资源，聚焦研发管线中的优势项目，经审慎考量，公司决定终止可溶性甘精赖脯双胰岛素注射液研发项目（BC Combo）（THDB0207注射液）临床研究开发工作，公司对该项 …See details»